ReviewPediatric dermatology2021
CARD14-associated papulosquamous eruption (CAPE) in pediatric patients: Three additional cases and review of the literature.
Review in Pediatric dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- CARD14-Associated Papulosquamous Eruption (CAPE): An Updated Review of Pathogenesis and Treatment.International journal of dermatology · 2026Review
- Clinical Characteristics of CARD14-Associated Papulosquamous Eruption and Evaluation of Therapeutic Efficacy of Secukinumab.Journal of inflammation research · 2025Article
- HomozygousBMJ case reports · 2024Article
- Case report: Successful treatment with biologics in a pediatric patient with a severe inflammatory skin disease and novelFrontiers in medicine · 2024Article
- Autoinflammatory Keratinization Diseases-The Concept, Pathophysiology, and Clinical Implications.Clinical reviews in allergy & immunology · 2023Review
- [Psoriasis in children and adolescents : Short update and guideline-based treatment].Dermatologie (Heidelberg, Germany) · 2023Review
- Treatment Options for Juvenile Pityriasis Rubra Pilaris.Paediatric drugs · 2023Review
- [Psoriasis in children and adolescents].Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde · 2023Review
- Tailored treatments in inborn errors of immunity associated with atopy (IEIs-A) with skin involvement.Frontiers in pediatrics · 2023Review
- Review
- Safety and Efficacy of Secukinumab in a Child with CARD14-Associated Papulosquamous Eruption: A Case Report and Review of Literature.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
CARD14-associated papulosquamous eruption (CAPE) is a proposed term that encompasses features ranging from psoriasis to pityriasis rubra pilaris (PRP) in association with CARD14 mutations. The early onset of the disease, prominent facial involvement, family history of an autosomal dominant trait, and poor response to conventional treatment are characteristics of CAPE that distinguish it from classical psoriasis and PRP. We describe the clinical features, family history, and response to therapy in three unrelated children with CAPE and compare these characteristics with those of previously described pediatric patients. Testing for CARD14 mutations in children with early onset of features of psoriasis or pityriasis rubra pilaris and resistance to conventional therapy should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.